KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Change in Accured Expenses: 2010-2024

Historic Change in Accured Expenses for TherapeuticsMD (TXMD) over the last 15 years, with Dec 2024 value amounting to -$1.0 million.

  • TherapeuticsMD's Change in Accured Expenses rose 199.30% to $425,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$182,000, marking a year-over-year increase of 95.57%. This contributed to the annual value of -$1.0 million for FY2024, which is 93.60% up from last year.
  • According to the latest figures from FY2024, TherapeuticsMD's Change in Accured Expenses is -$1.0 million, which was up 93.60% from -$15.7 million recorded in FY2023.
  • In the past 5 years, TherapeuticsMD's Change in Accured Expenses registered a high of $4.6 million during FY2021, and its lowest value of -$15.7 million during FY2023.
  • Over the past 3 years, TherapeuticsMD's median Change in Accured Expenses value was -$1.0 million (recorded in 2024), while the average stood at -$4.2 million.
  • In the last 5 years, TherapeuticsMD's Change in Accured Expenses plummeted by 468.68% in 2023 and then soared by 93.60% in 2024.
  • TherapeuticsMD's Change in Accured Expenses (Yearly) stood at $2.9 million in 2020, then spiked by 59.75% to $4.6 million in 2021, then dropped by 8.13% to $4.3 million in 2022, then slumped by 468.68% to -$15.7 million in 2023, then spiked by 93.60% to -$1.0 million in 2024.